CNTA — Centessa Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $3.56bn
- $3.43bn
Annual cashflow statement for Centessa Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -10.7 | -381 | -216 | -151 | -236 |
| Depreciation | |||||
| Non-Cash Items | 0.579 | 252 | 21.2 | 33.4 | 68.3 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.546 | -5.83 | -5.69 | -43.5 | 24.5 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -10.6 | -135 | -201 | -160 | -142 |
| Capital Expenditures | — | -0.186 | -1.14 | -0.169 | -0.034 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | 63.4 | 0.206 | -127 | 31.3 |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | — | 63.3 | -0.931 | -127 | 31.3 |
| Financing Cash Flow Items | — | -0.283 | -0.261 | 0 | -5.32 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 1.36 | 660 | 0.457 | 21.1 | 365 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -9.34 | 590 | -201 | -266 | 255 |